This study analyzed the cost-effectiveness of TAVR versus SAVR in 3110 intermediate-risk aortic stenosis patients from the PARTNER-2 trial. Using a Markov model, the authors found that TAVR is economically dominant from the perspective of lifetime cost-effectiveness in the US healthcare system. TAVR was estimated to save $8,000-$10,000 over the lifetime of the patient and to increase quality-adjusted survival by 0.15-0.27 years.
You are here:
Cost-Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Risk: Results From the PARTNER 2 Trial
Submitted by: Arie Blitz
Source: Circulation
Keywords:
Author(s): Suzanne J. Baron, Kaijun Wang, John A. House, Elizabeth A. Magnuson, Matthew R. Reynolds, Raj Makkar, Howard C. Herrmann, Susheel Kodali, Vinod H. Thourani, Samir Kapadia, Lars Svensson, Michael J. Mack, David L. Brown, Mark J. Russo, Craig R. Smith, John Webb, Craig Miller, Martin B. Leon , David J. Cohen, and on behalf of the PARTNER 2 Investigators
